• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Milestone Scientific Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    10/14/25 7:45:30 AM ET
    $MLSS
    Industrial Specialties
    Health Care
    Get the next $MLSS alert in real time by email
    false 0000855683 0000855683 2025-10-08 2025-10-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): October 8, 2025

     

    Milestone Scientific Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    (State or other jurisdiction

    of incorporation)

     

    001-14053

    (Commission

    File Number)

     

    13-3545623

    (IRS Employer

    Identification No.)

     

    220 South Orange Avenue,

    Livingston Corporate Park

    Livingston, New Jersey
    (Address of principal executive offices)

      070340
    (Zip Code)

     

    Registrant’s telephone number, including area code (973) 535-2717

     

    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

     

     

     

     

     

     

    Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

     

    On October 8, 2025, Milestone Scientific Inc. (“the Company”) received a letter from NYSE American LLC (“NYSE American” or the “Exchange”) stating that the Company is not in compliance with the continued listing standards as outlined in Section(s) 1003(a)(ii), and (iii) of the NYSE American Company Guide (the “Company Guide”). To maintain its listing, the Company must submit a plan of compliance by November 7, 2025, outlining the actions it has taken or will take to regain compliance. If the plan is accepted, the Company may be able to continue its listing but will be subject to periodic reviews by the Exchange. If the plan is not accepted or if it is accepted but the Company fails to comply with the continued listing standards by April 8, 2027, or if the Company does not make progress consistent with the plan, the Exchange will initiate delisting procedures as appropriate. The Company’s management is pursuing options to address the deficiency and intends to submit a compliance plan on or before the deadline set by the Exchange.

     

     

     

     


    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    Milestone Scientific Inc.

       
    Dated: October 14, 2025 By: /s/ Eric Hines
        Eric Hines
        Chief Financial Officer

     

     

     

    Get the next $MLSS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MLSS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MLSS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Milestone Scientific Delivers Stable Revenue and Reduces Operating Expenses by Over $500 Thousand in the Third Quarter of 2025

    ROSELAND, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced financial results and provided a business update for the third quarter ended September 30, 2025, highlighting continued progress on the Company's transformation and growth initiatives. Eric Hines, Chief Executive Officer of Milestone Scientific, stated, "During the third quarter, we made measurable progress executing our plan to build a leaner, more focused organization capable of sustained growth and improved profitability. Through disciplined cost management and operati

    11/13/25 4:00:00 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Schedules Third Quarter 2025 Financial Results and Business Update Conference Call

    ROSELAND, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Friday, November 14th, 2025, to discuss the company's financial results for the third quarter ended September 30, 2025, as well as the company's corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 164353. A webcast and replay of the call may be acc

    11/13/25 2:15:00 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Highlights Operational Progress and Growth Initiatives Under New Leadership

    ROSELAND, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update highlighting the Company's transformation and growth initiatives under the leadership of its new Chief Executive Officer, Eric Hines. Since joining Milestone Scientific two months ago, Mr. Hines has conducted a comprehensive review of the Company's operations and implemented a series of strategic actions designed to accelerate growth, strengthen its competitive position, and improve operating efficiency. Actions within the dental segment include expanding the Com

    10/14/25 7:50:00 AM ET
    $MLSS
    Industrial Specialties
    Health Care

    $MLSS
    SEC Filings

    View All

    Milestone Scientific Inc. filed SEC Form 8-K: Leadership Update

    8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)

    11/13/25 4:34:14 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    SEC Form 10-Q filed by Milestone Scientific Inc.

    10-Q - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)

    11/13/25 4:01:23 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    SEC Form DEF 14A filed by Milestone Scientific Inc.

    DEF 14A - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)

    11/12/25 4:07:57 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    $MLSS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Bp4 S.R.L. sold $84,884 worth of shares (194,427 units at $0.44), decreasing direct ownership by 2% to 8,896,765 units (SEC Form 4)

    4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)

    10/29/25 4:29:34 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    Large owner Bp4 S.R.L. sold $28,472 worth of shares (64,034 units at $0.44), decreasing direct ownership by 0.70% to 9,091,192 units (SEC Form 4)

    4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)

    10/23/25 4:49:27 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    Large owner Bp4 S.R.L. sold $27,273 worth of shares (50,158 units at $0.54), decreasing direct ownership by 0.44% to 9,155,226 units (SEC Form 4)

    4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)

    10/17/25 4:39:17 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    $MLSS
    Leadership Updates

    Live Leadership Updates

    View All

    Milestone Scientific Appoints Dr. Dawood Sayed to Board of Directors to Advance Commercial and Clinical Strategy in Pain Management

    ROSELAND, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Dawood Sayed, M.D., a nationally recognized leader in interventional pain medicine, to its Board of Directors, effective immediately. Dr. Sayed is a Professor of Anesthesiology and Pain Medicine at the University of Kansas Medical Center and currently serves as Division Chief of Pain Medicine, Director of Interventional Spine Services, and Director of the Center for Neuromodulation. With a robust clinical, academic, and policy background, he brings over a deca

    9/22/25 9:15:00 AM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Appoints Jason Papes as Senior Vice President, Global Head of Sales and Marketing

    ROSELAND. N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Jason Papes as Senior Vice President, Global Head of Sales and Marketing, effective immediately. Mr. Papes brings more than three decades of experience in sales, marketing, and business development within the healthcare industry, including leadership roles at large-cap medical technology companies and successful entrepreneurial ventures. His expertise spans orthopedics, neurology, pain management, and digital imaging, with a track record of building high-perfor

    8/6/25 8:30:00 AM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Appoints Eric C. Hines as Chief Executive Officer

    ROSELAND, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Eric C. Hines as Chief Executive Officer, effective immediately. Mr. Hines brings more than 25 years of leadership experience in scaling sales-driven enterprise software companies, serving customers across a range of industries, including healthcare. Most recently, he served as President of North America at Ex Libris, a division of Clarivate, where he led operations across the U.S., Canada, and Latin America and increased annual revenue from approximately $50 m

    8/1/25 8:30:00 AM ET
    $MLSS
    Industrial Specialties
    Health Care

    $MLSS
    Financials

    Live finance-specific insights

    View All

    Milestone Scientific Delivers Stable Revenue and Reduces Operating Expenses by Over $500 Thousand in the Third Quarter of 2025

    ROSELAND, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced financial results and provided a business update for the third quarter ended September 30, 2025, highlighting continued progress on the Company's transformation and growth initiatives. Eric Hines, Chief Executive Officer of Milestone Scientific, stated, "During the third quarter, we made measurable progress executing our plan to build a leaner, more focused organization capable of sustained growth and improved profitability. Through disciplined cost management and operati

    11/13/25 4:00:00 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Schedules Third Quarter 2025 Financial Results and Business Update Conference Call

    ROSELAND, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Friday, November 14th, 2025, to discuss the company's financial results for the third quarter ended September 30, 2025, as well as the company's corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 164353. A webcast and replay of the call may be acc

    11/13/25 2:15:00 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Achieves 25% Increase in Revenue for the Second Quarter of 2025

    ROSELAND, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provides a business update and reported financial results for the second quarter ended June 30, 2025. Neal Goldman, Chairman of the Board, stated, "We are pleased with our revenue performance in the second quarter, delivering a 25% increase in revenue to $2.3 million, driven by strong international dental sales, which more than doubled year-over-year. We also maintained a strong gross margin of 70%, reflecting the benefits of our high-margin dental business and disciplined cost management.

    8/14/25 4:15:00 PM ET
    $MLSS
    Industrial Specialties
    Health Care